Skip to content
Guavy Logo GUAVY
Sign up
Back to Guavy Wire
Forex

Supernus Pharmaceuticals Risk Score Hits 6.07 Amid Neutral Dollar Index

Guavy AI Editorial Team
Instruments
USD
Share

Supernus Pharmaceuticals Inc (SUPN) has been assessed for risk by TradingKey. The company's current risk assessment score is 6.07, ranking it 59 out of 155 in the Pharmaceuticals industry.

The U.S. Dollar Index is currently neutral, which has a neutral effect on the Pharmaceuticals domestic-focused industry.

Supernus' beta value is 0.55, indicating that its stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

More on Forex

Forex 1m ago

EUR/USD Struggles Near 1.1500 as 100-Day SMA Caps Recovery Attempts

Forex 3m ago

UK House Prices Tickle Up Amid Slowing Yearly Pace

Forex 3m ago

Bank of Japan Holds Rate, Cuts Inflation Forecast Amid Economic Slowdown

Disclaimer: Guavy is a data and market intelligence provider, not an investment advisor. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Guavy Logo GUAVY

Real-time market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy